Skip to main content
The NCI Community Hub will be retiring in May 2024. For more information please visit the NCIHub Retirement Page:https://ncihub.cancer.gov/groups/ncihubshutdown/overview
close

Presentation 2021: Pathology Informatics Summit - HTT project

Version 1
by (unknown)
Version 2
by (unknown)

Deletions or items before changed

Additions or items after changed

1 =[PresentationsandPublications Back to Presentations and Publications Main Page]=
2
3 = Pathology Informatics Summit 2021 =
4
5 -
==== Title: High Throughput Truthing (HTT): Pathologist Agreement from a Pilot Study =
+
==== Title: High Throughput Truthing (HTT): Pathologist Agreement from a Pilot Study ====
6 * 11:30 AM, Thursday, 06 May 2021
7 * Virtual
8
9 ==== Final presentation slides ====
10 [[File(20210506_PIsummit-Gallas-share.pdf)]]
11 +
12 +
==== Abstract ====
13 +
14 +
Background
15 +
* Artificial intelligence algorithms in digital pathology have enormous potential to increase diagnostic speed and accuracy. However, the performance of these algorithms must be validated against a reference standard before deployment in clinical practice. In this work, pathologists are considered as the reference standard. We studied interobserver variability in pathologists who evaluate stromal tumor-infiltrating lymphocytes (sTILs) in hematoxylin and eosin stained breast cancer biopsy specimens. Our ultimate goal is to create a validation dataset that is fit for a regulatory purpose.
16 +
Methods
17 +
* Following an IRB exempt determination protocol, we obtained informed consent of volunteer pathologist annotators prior to completing data collection tasks via two modalities: an optical light microscope and two digital platforms (slides were scanned at 40X). Pathologists were trained on the clinical task of sTIL density estimation before annotating pre-specified regions of interest (ROIs) across multiple platforms. The ROI selection protocol sampled ROIs in the tumor, tumor boundary, and elsewhere. Inter-pathologist agreement was characterized with the root mean-squared difference, which is analogous to the root mean-squared error but doesn’t require ground truth.
18 +
Results
19 +
* The pilot study accumulated 6,257 sTIL density estimates from 34 pathologists evaluating 64 cases, with 10 ROIs per case. The variability of sTIL density estimates in an ROI increases with the mean; the square roots of the reader-averaged mean-squared differences were 8.3, 17.7, and 40.4 as the sTIL density reference score increased from 0-10%, 10-40%, and 40-100%, respectively. We also found that the root mean-squared differences for some pathologists were considerably larger than others (as much as 120% larger than the next largest root mean-squared difference).
20 +
Conclusions
21 +
* Slides, images, and annotations were successfully provided by volunteer collaborators and participants, which created an innovative and thorough method for data collection and truthing. This pilot study will inform the development of statistical methods, simulation models, and sizing analyses for pivotal studies. The development and results of this validation dataset and analysis tools will be made publicly available to serve as an instructive tool for algorithm developers and researchers. Furthermore, the methods used to analyze pathologist agreement between density estimates are applicable to other quantitative biomarkers.
22
23 ==== Authors ====
24
25 * Katherine Elfer, PhD, MPH
26 * FDA/CDRH/OSEL/DIDSR
27 * Mohamed Amgad, MD
28 * Department of Pathology, Northwestern University
29 * Weijie Chen, PhD
30 * FDA/CDRH/OSEL/DIDSR
31 * Sarah Dudgeon, MPH
32 * CORE Center for Computational Health Yale-New Haven Hospital
33 * Rajarsi Gupta, MD/PhD
34 * Stony Brook Medicine Dept of Biomedical Informatics
35 * Matthew Hanna, MD
36 * Memorial Sloan Kettering Cancer Center
37 * Steven Hart, PhD
38 * Department of Health Sciences Research, Mayo Clinic
39 * Richard Huang, MD
40 * Massachusetts General Hospital/Harvard Medical School
41 * Evangelos Hytopoulos, PhD
42 * iRhythmTechnologies Inc
43 * Denis Larsimont, MD
44 * Department of Pathology, InstitutJules Bordet
45 * Xiaoxian Li, MD/PhD
46 * Emory University School of Medicine
47 * Anant Madabhushi, PhD
48 * Case Western Reserve University
49 * Hetal Marble, PhD
50 * Massachusetts General Hospital/Harvard Medical School
51 * Roberto Salgado, PhD
52 * Division of Research, Peter Mac CallumCancer Centre, Melbourne, Australia; Department of Pathology, GZA-ZNA Hospitals
53 * Joel Saltz, MD/PhD
54 * Stony Brook Medicine Dept of Biomedical Informatics
55 * Manasi Sheth, PhD
56 * FDA/CDRH/OPQE/Division of Biostatistics
57 * Rajendra Singh, MD
58 * Northwell health and Zucker School of Medicine
59 * Evan Szu, PhD
60 * Arrive Bio
61 * Darick Tong, MS
62 * Arrive Bio
63 * Si Wen, PhD
64 * FDA/CDRH/OSEL/DIDSR
65 * Bruce Werness, MD
66 * Arrive Bio